Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The Montes Claros site in Brazil is just one of many that Novo Nordisk has poured billions of dollars into as part of efforts to scale manufacturing capabilities. There was also the $16.5bn ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy and used to treat coexisting conditions.

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

while Novo Nordisk markets its semaglutide drug as Wegovy injection for weight management. Year to date, shares of PFE, LLY and NVO have lost 16.6%, 2.3% and 23.2%, respectively, compared with the ...